|
 |
sumatriptan succinateThis page contains recent news articles, when available, and an overview of sumatriptan succinate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: sumatriptan succinate (when available) Sumatriptan, an antimigraine drug, is structurally similar to serotonin. It is thought that the cerebral blood vessel constriction induced by activation of 5-HT1 receptors on those vessels may contribute to the antimigrainous effect of sumatriptan in humans. For the treatment of migraine attacks with or without aura in adults Mechanism Of Action: Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve. News Articles on Sumatriptan Mylan Pharma. Granted FDA Approval For ANDA For Sumatriptan ... - Aug 10, 2009 Mylan's Sumatriptan Succinate Tablets are the generic version of GlaxoSmithKline's migraine treatment Imitrex. The product is manufactured in Mylan's RTT News Sun Pharmaceutical's Generic Cancer, Migraine Drugs Get US OK - Aug 11, 2009 The company has also received approval for 25-mg, 50-mg and 100-mg doses of sumatriptan succinate tablets, a version of GlaxoSmithkline PLC's (GSK) Imitrex, Wall Street Journal Ranbaxy wins FDA approval for generic migraine drug - Aug 12, 2009 According to Ranbaxy, sumatriptan succinate 25mg and 50mg tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Trading Markets (press release) Indian generics profit from Glaxo patent expiry - Aug 17, 2009 The final approvals for generic versions of the drug, named sumatriptan succinate tablets, are for Indian companies such as Orchid Healthcare, Business Standard Tax Reform Talks Bolster Stocks in India - Aug 13, 2009 3.9% or Rs.3.95 to Rs.105.25 after it received the final approval from the US Food and Drug Administration for its drug Sumatriptan Succinate tablets. 123Jump.com Genzyme to toss most Cerezyme batches; Novartis gets EU nod on ... - Aug 11, 2009 Report > Ranbaxy Laboratories got final FDA approval to make and sell sumatriptan succinate tablets, used to treat migraine. Report > Mylan also got the FDA FiercePharma Realty, Metals lift Sensex at day's high - Aug 13, 2009 ...that it has received the final approval from the US Food and Drug Administration for its drug Sumatriptan Succinate tablets, 25 mg, 50 mg and 100 mg. India Infoline.com Mylan erhält FDA-Genehmigung für Generika von GlaxoSmithKline ... - Aug 10, 2009 Der US-Generikahersteller Mylan teilte am Montag mit, die Genehmigung zum Vertrieb seiner generischen Version der Migränetabletten "Sumatriptan Succinate" N24 Börse BUYINS.NET: HNR, PRX, MENT, NLS, RTI, PQ Are Seasonally Biased To ... - Jul 2, 2009 Its principal generic products include Metoprolol succinate ER, Fluticasone, Meclizine Hydrochloride, Cabergoline, Sumatriptan succinate injection, Trading Markets (press release) Drug firms may exceed growth targets - Apr 19, 2009 ...with about 20 per cent growth, thanks to good revenues from sumatriptan succinate, an authorised generic version of GlaxoSmithKline (GSK)'s Imitrex. Business Standard Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate ... - Feb 25, 2009 Sumatriptan Succinate Injection is not for use in the management of hemiplegic or basilar migraine. Bedford Laboratories will supply Sumatriptan Succinate PR Newswire (press release) Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results - Mar 2, 2009 Revenues for the fourth quarter 2008 increased 4.0% compared with the same period in 2007 due primarily to the launch of sumatriptan succinate injection, PR Newswire (press release) Wockhardt gets USFDA nod for Ranitidine syrup - Feb 23, 2009 Recently, the company had received final approval from the US Food and Drug Administration (USFDA) to market Sumatriptan Succinate injectable/ injection, Myiris.com Only 6 drug majors post better results - 04 Feb 2009 This was mainly due to exclusive gains from the launch of an authorised generic version of GlaxoSmithKline's Imitrex (Sumatriptan Succinate) in the US since Business Standard, Dr. Reddy's Labs Turns To profit in Q3 - Update - Jan 20, 2009 The company said the growth was driven by the successful launch of the authorized generic version of GlaxoSmithKline's Imitrex, or sumatriptan succinate in RTT News, Dr. Reddy’s Q3 FY09 Revenue at Rs. 18401 million, EBITDA at Rs ... - Jan 20, 2009 ...the successful launch of the authorized generic version of GlaxoSmithKline’s Imitrex® (generic version: sumatriptan succinate), in late November 2008. WELT ONLINE, Dr. Reddy’s Laboratories back in black - Jan 20, 2009 Sumatriptan is an authorised generic version of GlaxoSmithKline’s Imitrex (generic version: sumatriptan succinate). Imitrex is prescribed for the treatment Hindu, Ranbaxy Lab swings to loss for FY 08 - Jan 22, 2009 The company settled all matters relating to possible patent litigation with GlaxoSmithKline (GSK) relating to Sumatriptan Succinate Tablets, Myiris.com, Dr. Reddy’s Launches Authorized Generic Version of Imitrex Tablets - Dec 1, 2008 In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, Pharmaceutical Processing, Par Pharmaceutical Companies Inc to ship Sumatriptan Succinate ... - Nov 7, 2008 A Sumatriptan Succinate Injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache Trading Markets (press release), Par Pharmaceutical Begins Shipment of Sumatriptan Injection - Nov 6, 2008 Sumatriptan Succinate Injection is indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster Earthtimes (press release), الـ LSD... أنقذني من الصداع العنقودي! - Nov 19, 2008 علاوة على ذلك، أظهرت البيانات الصØية التي قدمتها خدمات إدارة المعلومات أن المبيعات السنوية من دواء Sumatriptan Succinate Ù?ÙŠ الولايات المتØدة خلال العامين الجريدة, Ranbaxy-GSK submits IND application for respiratory inflammation ... - Oct 13, 2008 The terms of the settlement, allowed Ranbaxy to distribute a generic version of Sumatriptan Succinate tablets in the 25mg, 50mg and 100mg strengths in the domain-B, Wockhardt gets nod for Promethazine hydrochloride injection - Sep 26, 2008 Recently, the company received tentative approval from USFDA to make and sell Sumatriptan Succinate injection, in the strength of 6 mg/0.5 ml. Myiris.com, Wockhardt gets USFDA nod for Promethazine hydrochloride injection - Sep 28, 2008 Recently, the company has received tentative approval from USFDA to produce and market Sumatriptan Succinate injection, in the strength of 6 mg/0.5 ml. Stock Watch, LSD cured my headache - Oct 6, 2008 Besides, according to IMS Health data, annual sales of sumatriptan succinate tablets in the US over 2006/07 were $950m. Why spend millions developing a Independent, Wockhardt gets tentative approval for Sumatriptan Succinate - Aug 25, 2008 Sumatriptan Succinate is the generic version of GlaxoSmithKline (GSK) Imitrex injection. The drug is prescribed for the treatment of a migraine attack with TopNews, Wockhardt Gets Tentative US FDA OK For Sumatriptan Succinate - Aug 24, 2008 BY) has received tentative approval from the US Food and Drug Administration to make and sell Sumatriptan Succinate, the generic version of GlaxoSmithKline Smartmoney.com Dr Reddy`s may miss sales forecast, say analysts - Jul 5, 2008 Dr Reddy's has forecasted a 25 per cent sales growth in the financial year 2009 mainly due to the demand for the generic version of sumatriptan succinate. Business Standard, Indian generic companies may tread Ranbaxy path - Jun 18, 2008 Ranbaxy had said “all matters relating to possible patent litigationâ€? with GSK on the latter’s Imitrex (sumatriptan succinate) have been settled. Economic Times, Meet Malav, the charismatic CEO of Ranbaxy - Jun 11, 2008 ...and settled with GSK over Sumatriptan Succinate, the generic version of GSK's Imitrex; Ranbaxy would launch the generic drug in the US in December 2008. Rediff, Par Increases Its Migraine Drug-Profit Share - May 7, 2008 Under the revised deal, Par's profit share from sales of sumatriptan succinate injection, a generic version of GlaxoSmithKline's Imitrex Injection that NJBIZ, Dr Reddy’s signs off a forgettable year - May 21, 2008 ...blockbuster anti-migrane drug, Imitrex, generically known as Sumatriptan Succinate which is worth around $1 billion in sales per year. Sify, Malav at work - May 5, 2008 ...and settled with GSK over Sumatriptan Succinate, the generic version of GSK's Imitrex; Ranbaxy would launch the generic drug in the US in December 2008. Business Standard, Ranbaxy's net profit at USD 39mn (Rs 1530 mn), + 19% - Apr 22, 2008 Ø The Company settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version Moneycontrol.com (press release), BeaconEquity.com - POZEN Inc. (POZN) Receives FDA Approval for ... - Apr 21, 2008 Treximet is GSK’s proposed brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with GSK’s RT Emailwire Stocks on the Move - PTSC, POZN, GSK, VNGM - Apr 16, 2008 Trexima is a proprietary single tablet containing sumatriptan succinate and naproxen sodium. How They Trade: POZN has a 52 week high of $19.75 and a 52 week TransWorldNews (press release), BUYINS.NET: FTWR, ICXT, POZN, ACTC, EDNE, LNVGY Have Also Been On ... - Apr 14, 2008 Trexima is a proprietary single tablet containing sumatriptan succinate and naproxen sodium. The company entered into a collaboration and license agreement Trading Markets (press release), Generic Ultram - Feb 29, 2008 Do not reaction hives difficulty breathing sumatriptan succinate. Ultram is one, of credit cards. Make sure that are related; to an unborn baby. Fatman Games Aurobindo gets provisionary approval to produce Sumatriptan ... - Feb 1, 2008 Aurobindo Pharma Ltd has got provisionary approval to develop and market the Sumatriptan Succinate Tablets in dosage of 25mg, 50mg and 100mg. Stock Watch, Aurobindo gets approval for Sumatriptan Succinate tabs - Feb 1, 2008 Sumatriptan Succinate Tablets are the generic equivalent of GlaxoSmithKline's Imitrex® Tablets, which are indicated for the treatment of acute migraine Moneycontrol.com (press release), Aurobindo gets US FDA nod for Sumatriptan tablets - Jan 31, 2008 The annual sales of the Sumatriptan succinate tablets in the US were around 950 million dollars last year, according to data from international consulting Hindu, Aurobindo Pharma gets USFDA nod for Sumatriptan - Jan 31, 2008 MUMBAI: Aurobindo Pharma has received tentative approval from the US Food and Drug Administration to manufacture and market Sumatriptan Succinate tablets Economic Times, Aurobindo Pharma gets FDA tentative nod for generic version of GSK ... - Jan 31, 2008 Annual sales of Sumatriptan Succinate Tablets in the US to end-March 2007, were 950 mln usd, according to IMS Health (nyse: RX - news - people ) data. Forbes, Aurobindo Pharma gets US nod for sumatriptan tablets - Feb 1, 2008 ...on Friday it received tentative approval from the US Food and Drug Administration for its sumatriptan succinate tablets, used to treat acute migraine. Therapeutics Daily (subscription) (press release), Ranbaxy, GSK settle Imitrex patent issue - Jan 21, 2008 NEW DELHI: Ranbaxy announced that it has settled all matters relating to possible patent litigation with GlaxoSmithKline regarding Sumatriptan Succinate Times of India, Ranbaxy, GlaxoSmithKline reach settlement - Jan 21, 2008 Sumatriptan Succinate tablets are the generic version of GlaxoSmithKline’s Imitrex Tablets. The terms of the settlement provide that Ranbaxy may distribute Hindu, Aurobindo gets USFDA nod for generic Imitrex - Jan 31, 2008 Aurobindo Pharma has received the US Food & Drug Administration (FDA) nod to market sumatriptan succinate in the United States. Business Standard, Indian Companies Settle Drug Suit - Jan 21, 2008 Ranbaxy, India's largest pharmaceutical company by sales, said the settlement over sumatriptan succinate, the generic version of GlaxoSmithKline's Imitrex, Wall Street Journal Ranbaxy settles generic sale dispute with GSK - Jan 21, 2008 The Gurgaon-based company said it has settled all matters relating to possible patent litigation with GSK regarding Sumatriptan Succinate tablets, Economic Times, India's Ranbaxy says settles issues with GSK over generic Imitrex ... - Jan 20, 2008 ...settled all matters with GlaxoSmithKline (NYSE:GSK) (GSK) related to its Sumatriptan Succinate tablets, the generic version of GSK's Imitrex tablets. CNNMoney.com Ranbaxy, GSK settle Imitrex patent dispute - Jan 20, 2008 Ranbaxy Laboratories has settled a patent litigation in the US with drug major GlaxoSmithKline (GSK) relating to Imitrex (sumatriptan succinate tablets), Business Standard, India Ranbaxy settles with GlaxoSmithKline on Imitrex - Jan 20, 2008 Under the terms of the settlement, Ranbaxy may sell a generic version, sumatriptan succinate tablets, in multiple strengths in the United States from Reuters Ranbaxy Announces Settlement of Possible Imitrex(R) Litigation ... - Jan 21, 2008 The terms of the settlement provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg, 50 mg and 100 mg SunHerald.com, Ranbaxy settles patent litigation with GlaxoSmithKline - Jan 21, 2008 The terms of the settlement provide that Ranbaxy may distribute a generic version of sumatriptan succinate tablets (in the 25mg, 50mg and 100mg strengths) Trading Markets (press release), Ranbaxy Settles Imitrex Dispute with GlaxosmithKline - Jan 21, 2008 The settlement allows Ranbaxy to distribute the generic version of the drug, Sumatriptan Succinate Tablets in the United States starting at the expected International Business Times, Ranbaxy settles patent dispute with GSK - Jan 21, 2008 Dr Reddy’s, which has an agreement with GSK to sell “authorised genericâ€? version of the drug will also be selling sumatriptan succinate tablets, Hindu Business Line, • Ranbaxy to Sell Copycat Migraine Med - Jan 21, 2008 The settlement provides that India-based Ranbaxy, which has its US headquarters in Princeton, may distribute sumatriptan succinate tablets, NJBIZ, Ranbaxy Labs Settles With GlaxoSmithKline On Imitrex - Quick Facts ... - Jan 21, 2008 As per the settlement, Ranbaxy might sell a generic version, sumatriptan succinate tablets, in multiple strengths in the United States from December 2008. RTT News, Ranbaxy, GSK Settles ‘Imitrex’ Patent Dispute - Jan 23, 2008 Dr. Reddy, which has an agreement with GSK to sell authorised generic drug version will also be selling sumatriptan succinate tablets, or generic Imitrex Stock Watch, Dr. Reddy's, Ranbaxy Announce Settlements - Jan 28, 2008 ...announced it had settled matters relating to possible patent litigation with GlaxoSmithKline (GSK) over Imitrex (sumatriptan succinate) tablets. FDA news (subscription), GSK deal to net Ranbaxy $90 mn in ’09 - Jan 21, 2008 A Ranbaxy spokesperson insisted the firm would enjoy a full exclusivity period for sumatriptan succinate (the chemical name of Imitrex) for 25mg, Livemint, Nonsurgical Treatment for Hallux Abducto Valgus with Botulinum Toxin A - Jan 17, 2008 The patient took sumatriptan succinate as needed for migraines and denied allergies. Her family history was significant for cardiovascular disease and high Journal of the American Podiatric Medical Association (subscription) Pozen Announces Trexima(TM) (Sumatriptan Succinate and Naproxen ... - Nov 1, 2007 POZEN Inc. (NASDAQ:POZN) announced today that its amended response to the FDA approvable letter for Trexima received on August 1, 2007 has been accepted for WELT ONLINE, Is Your Headache a Migraine？ - Oct 29, 2007 ...(sumatriptan succinate) Tablets. Now I have a migraine-specific medicine that works for me. My advice to people who regularly get bad headaches is to learn 金èž?ç•Œ, BUYINS.NET: SNP, CTEL, NINE, OFIX, POZN, ADVR Have Been Added To ... - Oct 23, 2007 Trexima is a proprietary single tablet containing sumatriptan succinate and naproxen sodium. The company entered into a collaboration and license agreement Trading Markets (press release), POZN: Sees Gains on Friday from FDA Update of Trexima(TM) - Oct 5, 2007 Trexima is a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with GSK's RT Technology(TM), and naproxen sodium, Trading Markets (press release), [an error occurred while processing this directive] [an error occurred while processing this directive] Brand Names/Synonyms: sumatriptan succinate is also known by the following brand names and/or synonymsCHEMBANK1724; Imigran; Imitrex; Sumatran; Sumatriptan; Sumatriptan Succinate; Sumatriptanum [Inn-Latin]; Sumax Drug Category: sumatriptan succinate is categorized under the following by the FDA: Vasoconstrictor Agents; Selective Serotonin Agonists; ATC:N02CC01 Dosage Forms: Tablets; Injection; Nasal spray Absorption: ~15% Interactions: Interactions for Sumatriptan: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised. Chemical IUPAC Name: 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |